Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

CervoMed (CRVO) EBIT (2022 - 2025)

Historic EBIT for CervoMed (CRVO) over the last 10 years, with Q3 2025 value amounting to -$8.0 million.

  • CervoMed's EBIT fell 4906.95% to -$8.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$27.2 million, marking a year-over-year decrease of 10200.98%. This contributed to the annual value of -$18.2 million for FY2024, which is 13329.55% down from last year.
  • Latest data reveals that CervoMed reported EBIT of -$8.0 million as of Q3 2025, which was down 4906.95% from -$6.6 million recorded in Q2 2025.
  • CervoMed's EBIT's 5-year high stood at -$904054.0 during Q3 2022, with a 5-year trough of -$8.0 million in Q3 2025.
  • For the 4-year period, CervoMed's EBIT averaged around -$3.7 million, with its median value being -$2.7 million (2023).
  • Its EBIT has fluctuated over the past 5 years, first tumbled by 19590.37% in 2023, then tumbled by 4906.95% in 2025.
  • Over the past 4 years, CervoMed's EBIT (Quarter) stood at -$938823.0 in 2022, then plummeted by 164.21% to -$2.5 million in 2023, then tumbled by 191.92% to -$7.2 million in 2024, then decreased by 11.1% to -$8.0 million in 2025.
  • Its last three reported values are -$8.0 million in Q3 2025, -$6.6 million for Q2 2025, and -$5.3 million during Q1 2025.